Sunitinib in Treating Young Patients With Refractory Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of sunitinib in treating young
patients with refractory solid tumors. Sunitinib may stop the growth of tumor cells by
blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor.